Tag Archives for Medicare Part D

SSA Trustees Report Calls on Congress to Fix Social Security and Medicare

Published in RINewsToday on June 22, 2026

Congress faces the urgent legislative task of ensuring the long-term viability of the nation’s Social Security program. As in previous years, the Social Security Board of Trustees’ 2026 report warns that without congressional action, the OASI and DI Trust Funds will pay full benefits only through 2034. Afterward, payroll tax revenue will cover about 83% of scheduled benefits, highlighting the need for timely Congressional intervention.

Federal law requires that trust fund-financed programs such as Social Security and Medicare pay out only as much in benefits as they receive in revenues once their trust fund reserves run out.

According to the Social Security Administration (SSA), about 21% to 22% of the U.S. population currently receives Social Security benefits. The released Trustee’s report notes that at the end of 2025, Social Security paid benefits to more than 70 million Americans: 56 million retired workers and their dependents, 8 million disabled workers and their families, and 6 million survivors of deceased workers. Medicare covered an estimated 69.3 million people.

The Trustees also said that recent congressional actions, including the Social Security Fairness Act and changes to the taxation of Social Security benefits, weakened the program’s long-term financial outlook.

The Social Security Board of Trustees is the group that issues the annual report on the financial health of Social Security’s trust funds — the Old-Age and Survivors Insurance fund and the Disability Insurance fund.

It has six seats:

1.    Secretary of the Treasury — also the Managing Trustee

2.    Secretary of Labor

3.    Secretary of Health and Human Services

4.    Commissioner of Social Security

5.    Public Trustee appointed by the President and confirmed by the Senate

6.    Public Trustee appointed by the President and confirmed by the Senate

As of the 2026 Trustees Report, the current government-position trustees are:

·         Scott Bessent, Secretary of the Treasury and Managing Trustee

·         Keith E. Sonderling, Acting Secretary of Labor

·         Robert F. Kennedy Jr., Secretary of Health and Human Services

·         Frank J. Bisignano, Commissioner of Social Security

The two public trustee seats are currently vacant

Demographic Changes Strain Social Security Finances

The annual Trustees Report, released on June 9, said several long-term demographic trends strain the financial stability of Social Security, as fewer workers pay payroll taxes into the program to support a growing population of beneficiaries.

Americans live longer and collect benefits for more years, while millions of Baby Boomers continue to retire. Birthrates stay below historical levels, so fewer workers enter the labor force.  Lower levels of immigration increase financial pressure by reducing the number of workers who pay payroll taxes.

The combined Social Security trust funds are currently projected to pay full benefits through 2034. However, the outlook for the Old-Age and Survivors Insurance (OASI) Trust Fund has weakened slightly. Trustees project OASI reserves will be depleted in late 2032. At that point, revenues are expected to cover only about 78% of scheduled OASI benefits, compared to the overall 83% coverage for all Social Security benefits after combined depletion.

The Trustees Report also notes that Social Security’s disability program remains financially stable. The Disability Insurance (DI) Trust Fund is expected to stay adequately financed throughout the 75-year projection period and pay full benefits without interruption.

Taking a Look at Medicare

Also released on June 9, the 2026 Medicare Trustees Report found that Medicare remains financially stable in the near term but faces significant long-term funding shortfalls caused by rising health care costs and an aging population.

According to the Trustees, Medicare spending will grow faster than revenues dedicated to financing the program. The health care needs of retiring Baby Boomers, growing Medicare enrollment, rising medical costs, and increased spending for services used frequently by older adults—including skilled nursing care, home health care, and hospice services—largely drive this increase.

The Medicare Hospital Insurance (HI) Trust Fund, which pays for Medicare Part A services, is projected to be depleted in the second quarter of 2033—three months earlier than last year’s prediction. After depletion, Medicare Part A would be able to cover about 89% of its costs from incoming revenue. Part A covers inpatient hospital stays, skilled nursing facility services, home health care, and hospice care.

Congress must act within the next seven years to prevent significant reductions in Medicare payments to providers. Addressing the projected shortfall before the 2033 trust fund depletion is essential to avoid an estimated 11% funding gap.

Unlike Part A, Medicare Parts B and D are not expected to face trust fund insolvency because they are financed through a combination of beneficiary premiums and general federal revenues.

Max Richtman, President & CEO of the National Committee to Preserve Social Security and Medicare (NCPSSM), says a range of proposals could help extend the solvency of Medicare’s Hospital Insurance (HI) Trust Fund without reducing benefits.

Among the options, says Richtman, are raising the Medicare tax rate on earned and investment income above $400,000 from 3.8% to 5%, and closing loopholes that allow some high-income business owners to avoid Medicare taxes by structuring income in ways that escape both payroll taxes and the Net Investment Income Tax (NIIT). NCPSSM also supports redirecting revenue from the 3.8% NIIT—currently deposited into general federal revenues—directly to the HI Trust Fund, he says, noting that the group estimates this change could generate roughly $500 billion over 10 years.

In addition, Richtman recommends building on the prescription drug reforms in the Inflation Reduction Act by expanding Medicare’s ability to negotiate drug prices, accelerating negotiations as more medications are added, and extending inflation-rebate requirements to commercial insurance plans. Savings from these measures, he says, would be credited directly to the HI Trust Fund, further strengthening Medicare’s long-term outlook.

Reactions From Advocacy Groups and Lawmakers

In a statement, AARP CEO Dr. Myechia Minter-Jordan warned that the 2026 projections show Congress still must close a financing gap of nearly 20%, or Americans could face benefit reductions they cannot afford.

“This should be a wake-up call: Congress needs to act. Americans have worked hard and paid into Social Security their entire lives, and they deserve to count on it when they retire,” she said. “They planned for retirement, followed the rules, and now Congress must keep its promise by strengthening, not cutting, Social Security,” Minter-Jordan added, urging lawmakers to work across party lines to strengthen the program.

“The Social Security Trustees Report is a clarion call for Congress to strengthen the program now before the looming depletion of the trust fund becomes a full-blown crisis,” said NCPSSM’s Richtman in a released statement.

“If Congress fails to act, the combined retirement and disability trust fund reserves will run dry in 2034, and beneficiaries will suffer an automatic 17% cut—a scenario few want to see happen. Lawmakers should not wait until the last minute when options become more limited and remedies more costly,” he said.

Richtman also argued that benefit reductions are not necessary to restore Social Security’s financial health and that beneficiaries living on fixed incomes should not bear the burden of strengthening the program.

In a statement, Nancy Altman, president of Social Security Works, likewise emphasized that the Trustees Report demonstrates the consequences of inaction.

“As the Trustees Report plainly states, if there is insufficient revenue, Social Security benefits will be automatically cut,” Altman said.

On June 15, 2026, House Speaker Mike Johnson said during a Louisiana radio interview that Republicans would like to address the growth of mandatory federal spending programs in future budget discussions, including Social Security. He argued that the federal budget is increasingly driven by automatic spending commitments and said that Social Security and other entitlement programs “have to be adjusted and fixed.”

Responding to Johnson’s remarks, Altman argued that some Republican proposals would move Social Security toward privatization, a characterization that supporters of those proposals dispute. She also criticized proposals that would reduce future benefits rather than increase revenues to strengthen the program.

Public opinion surveys consistently show strong bipartisan support for preserving Social Security benefits. Altman argued that proposals to reduce benefits through means testing or other changes would be unpopular with voters and called on congressional candidates to explain how they would address the program’s long-term financing challenges.

During a June 10 morning hearing of the Joint Social Security and Work & Welfare Subcommittee with Social Security Commissioner Frank Bisignano, held in room 1100 at 100 Longworth House Office Building, Rep. Jason Smith (R-MO) noted that Social Security benefits have only been modified twice in 40 years, most recently in 1983, with only minor changes under his chairmanship of the House Committee on Ways and Means in 2025.

“Congress needs to get its act together to address Social Security and the insolvency that’s coming instead of poking blame at other people when it is our duty, our responsibility,” Smith said, urging bipartisan cooperation between Republicans and Democrats to reform the program. He called for the protection of vulnerable populations who depend entirely on Social Security for retirement and a dignified standard of living, particularly in the rural communities they represent.

“This latest report from the trustees is proof that Congress must step up now to protect Social Security before it’s too late. It’s only going to cost more and be more difficult to solve the longer we wait,” said Sen. Bill Cassidy (R-La.) in a statement issued on June 10, outlining his plan to rescue Social Security by creating a sovereign wealth fund independent of the Social Security Trust Fund.

Cassidy joined Sens. Thom Tillis (R-N.C.), Dick Durbin (D-Ill.), and Tim Kaine (D-Va.) in issuing a bipartisan statement following the release of the Trustees Report. The senators said that “Congress shouldn’t delay any longer” and urged lawmakers to begin debating and voting on proposals to strengthen Social Security’s long-term solvency.

Putting Social Security on the Ballot

The Trustees’ Report makes it very clear that Social Security and Medicare are not facing an immediate financial crisis. Both programs will continue paying benefits for years to come. However, these reports also warn Congress that delaying action will make the eventual policy solutions more difficult to achieve and potentially more disruptive.

Many Republican proposals focus on slowing future benefit growth through measures such as raising the retirement age, modifying cost-of-living adjustments, or expanding means testing, while many Democrats favor increasing revenues by requiring higher-income Americans to contribute more into the system.

Over a year ago, lawmakers introduced a major bill to rescue Social Security and Medicare. Senator Sheldon Whitehouse (D-RI) introduced the Medicare and Social Security Fair Share Act (S. 1690) to ensure both programs remain stable in the future. The plan raises money by closing tax loopholes for ultra-wealthy Americans, but it completely shields anyone making under $400,000 a year from paying higher taxes. Representative Brendan F. Boyle (D-PA) brought the exact same bill to the House floor at the same time.

Legislative proposals, such as Whitehouse’s, to adjust the taxable wage cap or apply payroll taxes to certain forms of investment income have also been offered as ways to ensure Social Security’s fiscal solvency.

A new voter education campaign is highlighting the financial challenges facing Social Security. Led by NCPSSM’s Richtman, the “Social Security is on the Ballot” initiative aims to build public support for legislative solutions, including Sen. Whitehouse and Rep. Boyle’s proposed Fair Share Act, to help secure funding for the program.

There are many issues competing for voters’ attention this year,” explains Richtman, “But few will have such a profound effect on your future. Voters should insist [at the ballot box] that the fundamental promise of Social Security be preserved – as the program is strengthened for the future,” he said.

This multi-faceted campaign will encompass social media, short web videos, special editions of our “You Earned This” podcast and radio show, mailings, and grass-roots engagement/activism.

For over 70 million older Americans who rely on their Social Security and Medicare benefits, the Trustees’ Reports deliver a very clear message: Congress must act sooner rather than kicking the proverbial can down the road (as it usually has). As the projected trust fund depletion dates draw closer, lawmakers will need to work across the aisle to strengthen these programs and ensure they remain financially sound for current beneficiaries and future generations.

___

For a copy of the 2026 Social Security Trustees Report, go to The 2026 OASDI Trustees Report

For a copy of the 2026 Medicare Trustees Report, go to 2026 Medicare Trustees Report

Medicare Enrolled will see Lower Costs on Select Drugs in 2026

Published in Blackstone Valley Call & Times on December 2, 2025

With Medicare Open Enrollment ending next week, the Centers for Medicare & Medicaid Services (CMS) has announced that last year’s Medicare negotiations produced a net savings of 44%—about $12 billion—on 15 widely used prescription drugs that treat cancer and other serious chronic conditions.

The new Maximum Fair Prices (MFPs) for these 15 drugs will take effect on January 1, 2027. Combined with the 10 drugs already negotiated—whose MFPs take effect January 1, 2026—a total of 25 drugs will have negotiated lower prices. These medications, used to treat conditions such as cancer, diabetes, asthma, and cardiovascular and neurological disorders, represent some of the highest Medicare Part D spending.

The Beginning of Drug Price Negotiations

Three years ago, after President Biden signed the Inflation Reduction Act (IRA) in August 2022, CMS began developing the process for Medicare’s first-ever drug price negotiations. On March 15, 2023, the federal agency issued its initial program guidance and received more than 7,500 public comments from consumer groups, patient advocates, drug manufacturers, and pharmacies. Revised guidance followed on June 30, 2023.

On August 29, 2023, CMS released the first list of 10 high-cost drugs selected for negotiation—marking the first time in Medicare’s history that it could negotiate directly with pharmaceutical companies.

Pharmaceutical industry groups and several companies attempted to block the law in court. In response, 70 organizations and 150,000 petition signers urged Merck, Bristol Myers Squibb, Janssen Pharmaceuticals, Astellas Pharma US, the Pharmaceutical Research and Manufacturers of America (PhRMA), and the U.S. Chamber of Commerce to drop their lawsuits. Multiple organizations also filed amicus briefs supporting the law.

Three years in process, and with courts ultimately allowing the program to proceed, that first round of 10 drugs with negotiated prices will take effect in 2026.

CMS Drug Negotiations Added 15 Drugs

On January 17th, CMS announced it had selected 15 additional drugs for the second cycle of negotiations under Medicare Part D and on November 25th, it was announced that agreements had been reached on all of them. These medications are among the most costly and most commonly used by Medicare beneficiaries, treating conditions such as cancer, diabetes, and asthma. The new round of negotiations is expected to save Medicare billions and strengthen the program’s long-term sustainability.

“This year’s results stand in stark contrast to last year’s,” said CMS Administrator Mehmet Oz, MD, in announcing the second cycle of negotiations.  “Using the same process with a bolder direction, we have achieved substantially better outcomes for taxpayers and seniors in the Medicare Part D program — not the modest or even counterproductive ‘deals’ we saw before.”

“Whether through the Inflation Reduction Act or President Trump’s Most Favored Nation policy, this is what serious, fair, and disciplined negotiation looks like,” adds CMS Deputy Administrator and Medicare Director Chris Klomp. “I’m deeply proud of our team, who execute exceptionally well to bring affordability to the country in everything we do.”

Between January 1 and December 31, 2024, approximately 5.3 million Medicare Part D enrollees used one or more of these 15 drugs. Total gross Part D spending for them was $42.5 billion, representing about 15% of all Part D drug costs.

Anthony Wright, executive director of Families USA, praised the newly released negotiated prices, stating that they show what is possible when “policymakers put patients before corporate profits.” Wright emphasized that these reductions build on the work of establishing the Drug Price Negotiation Program, which aims to provide financial relief to older adults and people with disabilities.

Wright noted that the first and second rounds of negotiated drugs together account for about one-third of Medicare Part D spending, with price reductions ranging from 38% to 85%. In 2027, beneficiaries using these drugs are projected to save $685 million in out-of-pocket costs. He added that the savings support both individual beneficiaries and the long-term sustainability of the Medicare program.

Despite pharmaceutical companies’ continued attempts to limit the program—through lawsuits and legislative provisions such as those in H.R. 1—Wright said the negotiation program remains “the most effective tool currently available to lower drug prices.”

“The Medicare Negotiation Program changed the trajectory of drug pricing in the United States, helping to reduce Big Pharma’s monopoly pricing power, which dictated prices to Americans on Medicare for two decades,” said Merith Basey, executive director of Patients for Affordable Drugs in a statement. “This second round of negotiations — now under President Trump — marks another major milestone, delivering continued savings for patients and taxpayers,” he said.

“The lower negotiated prices are more than numbers on a page. For patients who’ve been forced to work multiple jobs, cut pills in half, or choose between filling a prescription and buying groceries, these lower prices will bring long-overdue relief, flexibility, and stability,” added Basey.

“The requirement that Medicare negotiate lower prices for prescription drugs continues to pay dividends for older Americans and taxpayers,” adds Richard Fiesta, executive director of the Alliance for Retired Americans. “The announcement of lower drug prices for 15 high-priced drugs is a win for more than 5 million seniors who take these drugs to treat asthma, diabetes, lung disease and other serious conditions, and will soon pay less for their medications,” he says.

“The 4.4 million members of the Alliance are pleased that the Trump Administration has followed the law, negotiated these prices, and defended this law in court,” Fiesta says, calling on Congress to increase the number of drugs subject to price negotiations.

While the White House along with aging groups praise the impact of IRA’s Medicare drug negotiation provisions, the Pharmaceutical Research and Manufacturers of America (PhRMA) issued a statement calling it “flawed.”

“Whether it is the IRA or MFN, government price setting for medicines is the wrong policy for America. Price setting does nothing to rein in PBMs who decide which medicines are covered and what patients pay. In fact, many patients are facing additional coverage barriers and paying more out-of-pocket for medicines because of the IRA, warns Alex Schriver, Senior Vice President of Public Affairs.

“These flawed policies also threaten future medical innovation by siphoning $300 billion from biopharmaceutical research, undermining the American economy and our ability to compete globally,” states Schriver, noting that PhRMA members are stepping up to make medicines more affordable by enabling direct purchase at lower prices and investing in U.S. manufacturing and infrastructure.

Lower Drug Cost Legislation Introduced

Congressman John B. Larson (D-CT), a senior member of the House Ways and Means Committee, praised the latest CMS announcement, estimating that both negotiation rounds will save older Americans more than $2 billion per year in out-of-pocket costs. Larson noted that families and seniors continue to struggle with rising prices, especially for prescription drugs.  The lawmaker pushed to enable Medicare to negotiate drug prices to lower drug costs by the enactment of IRA.

Last week, House Democrats introduced the Lower Drug Costs for American Families Act, aimed at closing loopholes in H.R. 1 and further reducing prescription drug prices. The bill (H.R. 6166), introduced November 20 by Ranking Members Frank Pallone Jr. (Energy and Commerce), Richard Neal (Ways and Means), and Bobby Scott (Education and Workforce), has been referred to all three committees.

Key provisions of the bill would:

  • Extend Medicare’s price negotiation authority to all Americans with private insurance—covering more than 164 million people with employer-sponsored plans and over 24 million enrolled in Affordable Care Act plans
  • Apply inflation-based rebate protections to private insurance markets, potentially saving $40 billion over 10 years
  • Increase the number of negotiated drugs from 20 to 50 per year
  • Extend the $2,000 annual out-of-pocket prescription drug cap to privately insured patients
  • Cap insulin costs at $35 per month for those with private insurance
  • Close the orphan-drug loophole that allows companies to avoid negotiation
  • Require consideration of international drug prices to ensure Americans do not pay three to five times more than patients in other countries

Continue the Momentum

According to CMS, the agency will announce the specifics on 15 drugs for the third round of Medicare price negotiations by February 1, 2026. This new round will include drugs paid under Medicare Part B for the first time and will begin with negotiated prices effective January 1, 2028. CMS has already released final guidance for the program and will also use this process to select drugs for renegotiation in previous cycles. IRA also establishes an ongoing process where more drugs will be selected for negotiation in subsequent years.

A Dec. 2024 AARP survey found that almost 3 in 5 adults age 50 and older expressed concern about their ability to afford prescriptions over the near future.  Respondents included both Medicare beneficiaries and younger persons. About 96 percent of the respondents call on the government to do more to lower pharmaceutical prices.

AARP noted that this survey was taken right before a new $2,000 cap on out-of-pocket drug expenses took effect in 2025.

With the announcement of lower drug costs that result from Medicare’s round 2 drug negotiations, there is an  opportunity to build on this momentum for real change. Lawmakers can legislate to put the public’s health above profit by giving consumers more power to negotiate, making competition stronger, and keeping patients from having to pay too much out of pocket.

It is now time for Congress to act.

Cap on out— of-pocket costs for Medicare drug plan enrollees coming soon

Published in RINewsToday on September 2, 2024 

Back on Aug. 16th in 2022, President Joe Biden signed into law the Inflation Reduction Act of 2022 (IRA), it’s enactment lowering the health cost for millions of older Americans by lowering the high cost of prescription drugs by granting Medicare the power to directly negotiate drug prices with drug companies.  Rising drug costs were forcing some Medicare beneficiaries to cut their expenses by not filling a prescription or even skipping doses. This could lead to complications and side effects resulting in hospitalization, even death.

“AARP was instrumental in Congress passing the prescription drug law of 2022 to lower prices and out-of-pocket costs for Medicare enrollees,” said Jo Ann Jenkins, CEO of AARP in an Aug. 28 statement announcing the release of AARP’s new report. “As we approach January 2025, we want every senior in America to know that, thanks to the new annual cap which limits their out-of-pocket costs, they will have more money to invest in their families, spend on their broader health needs or simply save to achieve greater financial stability.”

Virtual Media Briefing Details Impact on IRA law

Last week, the Washington, DC-based AARP briefed the media on the state-level impact of the historic new federal protection for 56 million Medicare drug plan enrollees. The new law caps out-of-pocket prescription drug costs every year, beginning at $2,000 in January 2025. 

The nine-page Public Policy Institute report, released at the virtual media briefing, analyzes the number of enrollees (not receiving the Medicare low-income subsidy) that will benefit from the new cap by state, age, gender, and race between 2025 and 2029.

Nancy LeaMond, the chief advocacy and engagement officer for AARP, say putting the brakes to spiraling drug cost by enacting the IRA put money back into the pockets of millions of America’s retirees purchasing pharmaceuticals for their medical conditions. “Upwards of 95% of Americans, age 65 and older, have at least one chronic condition and close to 80% are dealing with 2 or more chronic conditions,” says LeaMond, like diabetes and heart disease, to debilitating neurological diseases like Parkinson’s and Ms.

“Prescription drugs are a lifeline, said LeaMond, stressing that medicine is only effective if you have the money to pay for it. The passage of IRA two years ago is already having a significant and positive impact on millions of Medicare beneficiaries who now don’t pay more than $35 a month for insulin and get free vaccines for things like shingles,” she noted. 

“There are even bigger savings coming down the pike, starting in January 2025. The total amount that folks enrolled in Medicare drug plans pay out of pocket for their prescriptions will be capped at $2,000 a year,” reports LeaMond.  

During the media briefing, Leigh Purvis, Prescription Drug Policy Principal, AARP Public Policy Institute, stated “one of the biggest challenges in the original Medicare Part D benefit was the lack of a cap on out-of-pocket spending.”  Even after reaching a certain limit, Medicare beneficiaries were still required to pay 5% of their drug costs, with no limit for those on expensive Medications, she said.

According to Purvis, out of pocket expenses could exceed $10,000 per year, “an unmanageable amount for anyone, but especially for a population with a Median annual income of $36,000. Because of this, AARP pushed for the inclusion of a cap on out-of-pocket spending for Medicare Part D, to be included in the IRA, she said.  And it was…

Purvis noted that 3 million Part D beneficiaries (who don’t receive the Medicare Part D low-income subsidy are expected to benefit from the $2,000 cap in 2025.  This number is expected to grow to over 4 million by 2029.  These Medicare drug plan enrollees would see average savings of roughly $1,100, or 56%, in 2025 for their prescription drugs. 

Purvis also gave a few other takeaways from the report.  On average,  approximately 1.4 million (40 percent) Medicare drug plan enrollees who reach the new out-of-pocket cap between 2025 and 2029 are estimated to see annual savings of $1,000 or more, and just over 420,000 (12 percent) will see savings of more than $3,000.  In addition, more than three-quarters of Medicare drug plan enrollees who will benefit in 2025 are between the ages of 65 and 84.

Finally, Paula Cunningham, AARP Michigan State Director (discussing  results of a state survey) and Diana Devito , who has lived with chronic lymphocytic leukemia for over 19 years, participated in the media briefing. Both reinforced  how the report’s numbers aren’t just statistics, they represent real people “who are being forced to make impossible choices.” 

Cunningham told a “heartbreak” story about a woman who had lost her husband, and she had to sell her wedding ring in order to pay for her prescription drugs. “She’s now deceased, but I will never forget her story, or the stories of people across this great state that we met who had to make difficult choices between paying rent or buying groceries to pay for their medications,” she said.

After experiencing the high prescription costs for treating life-threatening chronic disorder, Devito came to share how important a $2,000 cap can be “for people like me.”  She said, “It’s a real-life changer,” noting that everyone doesn’t understand that. “If you’re not taking one of these expensive drugs, you don’t realize the impact that it has on your life,” she added.

On Another Note…

U.S. Senator Jack Reed brings to my attention another Congressional report that details the Rhode Island specific data as to the impact of IRA on older Rhode Islanders.

According to the Congressional Joint Economic Committee (CJEC), this year, about 57,000 Rhode Island Medicare beneficiaries will save an average of roughly $200 each year because of IRA’s improvement to the Medicare Part D drug coverage. By 2025 this number would increase to 68,000 retirees, saving them an annual average of $340 on prescription drugs.

By allowing Medicare to negotiate with drug companies to bargain down the high cost of many lifesaving drugs, 29,000 retirees use drugs that are with the new negotiated prices, says the CJEC report.

For a copy of AARP Public Policy Institute’s Medicare Part D Out-of-Pocket Spending Cap, go to https://www.aarp.org/pri/topics/health/prescription-drugs/medicare-part-d-out-of-pocket-spending-cap-prescription-drug-costs/.

To learn more about AARP’s work to lower prescription drug prices, visit https://www.aarp.org/politics-society/advocacy/prescription-drugs/.

For a copy of CJEC’s report, go to https://www.jec.senate.gov/public/_cache/files/356ae3d2-af5e-4d32-bd42-fafc548173c5/ri-cost-savings-fact-sheet.pdf

For details how the IRA impacts older Rhode Island retirees, go to https://www.whitehouse.gov/wp-content/uploads/2022/08/Rhode-Island-Health-Care.pdf